BBSRC Portfolio Analyser
Award details
Translational investigation of a lithium mimetic on emotional and cognitive processing in healthy volunteers
Reference
BB/J021547/1
Principal Investigator / Supervisor
Dr Grant Churchill
Co-Investigators /
Co-Supervisors
Professor Philip Cowen
,
Professor Catherine Harmer
Institution
University of Oxford
Department
Pharmacology
Funding type
Research
Value (£)
152,136
Status
Completed
Type
Research Grant
Start date
30/07/2012
End date
30/04/2014
Duration
21 months
Abstract
unavailable
Summary
Bipolar disorder disease is a chronic illness characterized by recurrent episodes of aberrant mood that affects around 3% of the world's population. Current therapies for bipolar disorder such as lithium, valproic acid and atypical antipsychotics, such as seroquel, cause serious side effects including liver and kidney damage. There is therefore an urgent need for new therapies that allow long-term mood stabilisation in patients, but are more favourably tolerable. In this project, we propose to confirm the suitability of a known antioxidant that has proven to be safe in humans as a lithium replacement candidate. Our drug inhibits the enzyme inositol monophosphatase, a candidate therapeutic target of lithium and also alters mood and behaviour in animals in a manner similar to lithium. This drug, if successful therefore, would offer for the first time, the potential for physicians to treat bipolar patients without exposing them to harmful side effects.
Committee
Not funded via Committee
Research Topics
Neuroscience and Behaviour, Pharmaceuticals
Research Priority
X – Research Priority information not available
Research Initiative
Follow-On Fund (FOF) [2004-2015]
Funding Scheme
X – not Funded via a specific Funding Scheme
I accept the
terms and conditions of use
(opens in new window)
export PDF file
back to list
new search